Consumer Medicine Information (CMI) summary
The
full CMI on the next page has more details. If you are worried about using this medicine,
speak to your doctor or pharmacist.
This medicine is new or being used differently. Please report side effects. See the
full CMI for further details.
1. Why am I using Skyrizi?
Skyrizi contains the active ingredient risankizumab. Skyrizi is used to treat adults
with moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to
severe Crohn's disease, and moderate to severe ulcerative colitis.
2. What should I know before I use Skyrizi?
Check the list of ingredients at the end of the CMI. Do not use Skyrizi if you have
ever had an allergic reaction to any of them.
Talk to your doctor if you have any other medical conditions, take any other medicines,
or are pregnant or plan to become pregnant or are breastfeeding.
3. What if I am taking other medicines?
Some medicines may interfere with Skyrizi and affect how it works or Skyrizi may interfere
with other medicines and affect how they work.
4. How do I use Skyrizi?
5. What should I know while using Skyrizi?
|
Things you should do
|
Ensure you are up to date with your immunisations before you start therapy with Skyrizi.
Speak to your doctor if you think you have an infection.
Remind any doctor or dentist you visit that you are using Skyrizi.
|
|
Things you should not do
|
Do not stop using this medicine or change the dose without checking with your doctor.
|
|
Driving or using machines
|
Skyrizi is not expected to have any effect on your ability to drive or use machines.
|
|
Drinking alcohol
|
There is no information on the effects of using Skyrizi with alcohol.
|
|
Looking after your medicine
|
Store Skyrizi in the refrigerator at 2°C to 8°C. Do not freeze.
Keep it in the original carton until it's time to inject it to protect it from light.
|
6. Are there any side effects?
The more serious side effects include: Symptoms of a serious infection, including
fever, flu-like symptoms, night sweats, feeling tired or short of breath, a cough
that won't go away, warm, red, painful skin or painful rash with blisters.
The more common side effects include: upper respiratory infections with symptoms such
as sore throat and stuffy nose, tiredness, headache, injection site reactions, itching,
fungal skin infection.
This medicine is subject to additional monitoring. This will allow quick identification
of new safety information. You can help by reporting any side effects you may get.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems .
Active ingredient:
risankizumab (ri-zan-ki-zyu-mab)
Full Consumer Medicine Information (CMI)
This leaflet provides important information about using Skyrizi. You should also speak to your doctor or pharmacist if you would like further information
or if you have any concerns or questions about using Skyrizi.
Where to find information in this leaflet:
1. Why am I using Skyrizi?
Skyrizi contains the active ingredient risankizumab which is a type of protein called
a monoclonal antibody. It works by stopping a protein in the body called IL-23 which
causes inflammation.
Psoriasis: Skyrizi reduces inflammation and can therefore help to improve skin clearance
and the appearance of nails. It also reduces symptoms of plaque psoriasis such as
burning, itching, pain, redness and scaling.
Psoriatic Arthritis: Skyrizi reduces the inflammation and can therefore help to reduce
pain, stiffness and swelling in and around your joints, pain and stiffness in your
spine, psoriatic skin rash, psoriatic nail damage and it may limit damage to the bone
and cartilage in your joints. These effects can ease your normal daily activities,
reduce tiredness and improve your quality of life.
Crohn's disease: Skyrizi reduces inflammation and can therefore help reduce signs
and symptoms such as abdominal pain, diarrhoea and tiredness, as well as improve healing
of the bowel, which can help improve your quality of life.
Ulcerative Colitis: Skyrizi reduces inflammation and can therefore help to reduce
signs and symptoms of your disease such as abdominal pain, bloody stools, frequent
and loose stools, and tiredness, as well as improve healing of the bowel, which can
help improve your quality of life.
2. What should I know before I use Skyrizi?
Warnings
Do not use Skyrizi if:
1. you are allergic to risankizumab, or any of the ingredients listed at the end of this
leaflet.
2. you have an infection considered by your doctor to need special attention.
Check with your doctor if you:
have an infection now
have had an infection that keeps coming back
have or have had tuberculosis
have had a recent vaccination or are scheduled for any immunisations
take any medicines for any other condition
During treatment, you may be at risk of developing certain side effects. It is important
you understand these risks and how to monitor for them. See additional information
under Section
6. Are there any side effects?
Pregnancy and breastfeeding
Make sure your doctor is aware that you are pregnant or plan to become pregnant or
are breastfeeding or plan to do so.
Children
Skyrizi is not indicated for patients under the age of 18 years, therefore Skyrizi
is not recommended for children.
3. What if I am taking other medicines?
Tell your doctor or pharmacist if you are taking any other medicines, including any
medicines, vitamins or supplements that you buy without a prescription from your pharmacy,
supermarket or health food shop.
Do this even though Skyrizi is not expected to be affected by other medicines, nor
is it expected to interfere with other medicines.
4. How do I use Skyrizi?
How much to use
Psoriasis/Psoriatic arthritis:
The dose is 150 mg. After the first dose, you will have the next dose 4 weeks later
and then every 12 weeks. If using the 150 mg/mL pre-filled syringe or pre-filled pen,
each dose is given as one 150 mg injection. If using the 75 mg/0.83 mL pre-filled
syringe, each dose is given as two 75 mg injections.
Crohn's disease and Ulcerative colitis:
You will begin treatment with Skyrizi with a starting dose (known as induction phase)
which will be given by your doctor, nurse or healthcare professional through a drip
in your arm (intravenous infusion).
Starting doses
|
|
How much?
|
When?
|
|
Crohn's disease
|
600 mg
|
Week 0 (When your doctor tells you)
|
|
600 mg
|
Week 4 (4 weeks after your first starting dose)
|
|
600 mg
|
Week 8 (4 weeks after your second starting dose)
|
|
Ulcerative colitis
|
1200 mg
|
Week 0 (When your doctor tells you)
|
|
1200 mg
|
Week 4 (4 weeks after your first starting dose)
|
|
1200 mg
|
Week 8 (4 weeks after your second starting dose)
|
Afterwards, you will receive, or you will be able to inject SKYRIZI using a pre-filled
cartridge with an on-body injector as an injection under your skin (subcutaneous injection).
Maintenance doses
|
|
How much?
|
When?
|
|
Crohn's disease
|
First maintenance dose
|
360 mg
|
Week 12 (4 weeks after the last starting dose)
|
|
Further doses
|
360 mg
|
Week 20 and every 8 weeks, starting after the first maintenance dose
|
|
Ulcerative colitis
|
First maintenance dose
|
180 mg or 360 mg
|
Week 12 (4 weeks after the last starting dose)
|
|
Further doses
|
180 mg or 360 mg
|
Week 20 and every 8 weeks, starting after the first maintenance dose
|
Follow all the instructions given to you and continue to use Skyrizi until your doctor
tells you to stop.
How to inject Skyrizi
Skyrizi 75 mg/0.83 mL pre-filled syringe, 150 mg/mL pre-filled syringe and pen, 180
mg/1.2 mL pre-filled cartridge with on-body injector and 360 mg/2.4 mL pre-filled
cartridge with on-body injector are injected under your skin (subcutaneous injection).
It can be injected by the patient or by someone else, such as a family member, friend
or carer.
An injection should not be attempted until proper training has been received on the
correct injection technique.
Read the instructions for preparing and giving a Skyrizi injection that are supplied
with the product.
Skyrizi 600 mg/10 mL
Skyrizi 600 mg/10 mL single-use vial for intravenous infusion will be given by your
doctor, nurse or health care professional through a vein in your arm (intravenous
infusion).
Skyrizi 600 mg/ 10 mL should be prepared and given by a healthcare professional using
aseptic technique.
Click on the link for the instructions on how to inject 75 mg/0.83mL pre-filled syringe:
Click on the link for the instructions on how to inject 150 mg/mL pre-filled syringe:
https://www.medsinfo.com.au/media/veis150s
Click on the link for the instructions on how to inject 150 mg/ mL pen:
Click on the link for the instructions on how to inject using the 180 mg/1.2 mL pre-filled
cartridge with on-body injector:
https://www.medsinfo.com.au/media/vei180pc
Click on the link for the instructions on how to inject using the 360 mg/2.4 mL pre-filled
cartridge with on body injector:
https://www.medsinfo.com.au/media/vei360pc
Please look for the QR code on the medicine pack. Scan this code with your smart phone
for more information on Skyrizi.
If you forget to inject Skyrizi
It is important that you use your medicine as instructed.
If you miss your dose at the usual time, inject Skyrizi as soon as you remember, and
continue injecting the next dose at the usual time on your next scheduled day.
Do not inject a double dose to make up for the dose you missed.
If you inject too much Skyrizi
You should immediately:
phone the Poisons Information Centre in Australia (by calling
13 11 26), in New Zealand the National Poisons Centre (by calling 0800 POISON or 0800 764
766) or
contact your doctor, or
go to the Emergency Department at your nearest hospital.
You should do this even if there appear to be no signs of discomfort or poisoning.
5. What should I know while using Skyrizi?
Things you should do
Ensure you are up to date with your immunisations before you start therapy with Skyrizi.
Keep all your doctor’s appointments so your progress can be tracked.
Blood tests to check your liver (Crohn's disease or ulcerative colitis)
Blood tests will be taken before, during and up to 12 weeks treatment
Call your doctor straight away if you:
Become pregnant while using Skyrizi.
Remind any doctor or dentist you visit that you are using Skyrizi.
Things you should not do
Do not inject Skyrizi if the liquid looks cloudy or contains flakes or large particles.
Do not stop using this medicine or change the dose without checking with your doctor.
Driving or using machines
Skyrizi is not expected to have any effect on your ability to drive or use machines.
Drinking alcohol
There is no information on the effects of using Skyrizi with alcohol.
Looking after your medicine
Follow the instructions on the carton on how to take care of your medicine properly.
Keep Skyrizi in the refrigerator (at 2°C to 8°C). Do not freeze.
Keep in the original carton to protect it from light.
If needed, you may also store Skyrizi 150 mg/mL pen or pre-filled syringe, Skyrizi
180 mg/1.2 mL or 360 mg/2.4 mL pre-filled cartridge with on-body injector one time
out of the refrigerator (up to a maximum of 25°C) for up to 24 hours in the original
carton to protect from light.
If unopened and stored below 25°C for less than 24 hours, you may return the Skyrizi
150 mg/mL pen or pre-filled syringe, or 180 mg/1.2 mL or 360 mg/2.4 mL prefilled cartridge
with on-body injector to the refrigerator.
The pre-filled syringe can be taken out of the fridge 15 to 30 minutes before injected,
provided it is kept in the carton. This may make the injection more comfortable.
The pre-filled pen can be taken out of the fridge 30 to 90 minutes before injected,
provided it is kept in the carton.
The pre-filled cartridge with on-body injector can be taken out of the fridge to reach
room temperature for 45 to 90 minutes before injected, provided they are kept in the
carton. Keep out of direct sunlight.
Do not use this medicine after the expiry date.
Keep it where young children cannot reach it.
When to discard your medicine
Throw away the used syringe, pen or on-body injector immediately after injecting,
as instructed by your doctor or nurse.
Getting rid of any unwanted medicine
If you no longer need to use this medicine or it is out of date, take it to any pharmacy
for safe disposal.
6. Are there any side effects?
All medicines can have side effects. If you do experience any side effects, most of
them are minor and temporary. However, some side effects may need medical attention.
See the information below and, if you need to, ask your doctor or pharmacist if you
have any further questions about side effects.
Less serious side effects
|
Less serious side effects
|
What to do
|
|
Upper respiratory tract infection:
sore throat
stuffy nose
Skin:
fungal skin infection, such as athlete's foot (tinea)
pain, or redness at the injection site
small raised red bumps on the skin
General:
headache
feeling especially tired
Other side effects (Crohn's disease or ulcerative colitis)
Muscle or bone:
joint pain and/or swelling
back pain
Gut:
pain in belly
Urinary tract infection:
burning when passing urine and/or passing urine more often
General:
fever
anaemia
|
Speak to your doctor if you have any of these less serious side effects and they worry
you.
|
Serious side effects
Tell your doctor or pharmacist if you notice anything else that may be making you
feel unwell.
Other side effects not listed here may occur in some people.
Reporting side effects
After you have received medical advice for any side effects you experience, you can
report side effects to the Therapeutic Goods Administration online at
www.tga.gov.au/reporting-problems . By reporting side effects, you can help provide more information on the safety of
this medicine.
Always make sure you speak to your doctor or pharmacist before you decide to stop
taking any of your medicines.
7. Product details
This medicine is only available with a doctor's prescription.
What Skyrizi contains
|
Active ingredient
(main ingredient)
|
risankizumab
|
|
Other ingredients 75 mg/0.83 mL
(inactive ingredients)
|
sodium succinate hexahydrate
succinic acid
sorbitol
polysorbate 20
water for injections
|
|
Other ingredients 150 mg/mL,600 mg/10 mL, 180 mg/1.2 mL and 360 mg/2.4 mL
(inactive ingredients)
|
sodium acetate trihydrate
glacial acetic acid
trehalose dihydrate
polysorbate 20
water for injections
|
Do not take this medicine if you are allergic to any of these ingredients.
Skyrizi contains 34 mg sorbitol in each 75 mg/0.83mL injection.
Not all presentations may be marketed.
What Skyrizi looks like
Skyrizi 75 mg/0.83 mL is a colourless to slightly yellow liquid and is supplied in
a prefilled syringe with needle guard. The liquid may contain tiny white or clear
particles. Do not use if liquid is cloudy or contains flakes or large particles. Two
syringes are supplied per carton. The carton also contains two alcohol pads (AUST
R 304226).
Skyrizi 150 mg/mL liquid should look clear to yellow and may contain tiny white or
clear particles. Do not inject if the liquid is cloudy or contains flakes or large
particles. It is supplied in a 150 mg/mL pre-filled syringe with needle guard or a
150 mg/mL pre-filled pen. Each carton contains one pre-filled syringe (AUST R 342813)
or one pre-filled pen (AUST R 342814).
Skyrizi 600 mg/10 mL liquid should look colourless to slightly yellow and may contain
tiny white or clear particles. Do not inject if the liquid is cloudy or contains flakes
or large particles. It is supplied as a concentrate solution for infusion in a single
dose 600 mg/10 mL vial. Each carton contains one vial (AUST R 375984).
Skyrizi 180 mg/1.2 mL and 360 mg/2.4 mL liquid should look clear and colourless to
yellow and may contain tiny white to clear particles. Do not inject if the liquid
is cloudy or contains flakes or large particles. It is supplied in a 180 mg/1.2 mL
pre-filled cartridge with on-body injector or a 360 mg/2.4 mL pre-filled cartridge
with on-body injector. Each carton contains one pre-filled cartridge with on-body
injector (360 mg/2.4 mL - AUST R 375976 or 180 mg/1.2 mL - AUST R 427219).
Who distributes Skyrizi?
SKYRIZI is distributed in Australia by:
AbbVie Pty Ltd
241 O'Riordan Street
Mascot NSW 2020
Australia
SKYRIZI is distributed in New Zealand by:
AbbVie Limited
6th Floor, 156-158 Victoria Street
Wellington 6011
New Zealand
This leaflet was prepared in November 2024.
Version 9
© 2023 AbbVie. All rights reserved.
SKYRIZI® is a registered trademark of AbbVie Biotechnology Ltd.